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ABSTRACT
Objective: In order to provide concrete context to research on biologicals for severe asthma 
we explore the everyday experiences of patients living with severe asthma and using 
biologicals.
Methods: We use a multi-method qualitative research-design including existing patient 
narratives, ten life-history interviews with patients using benralizumab (N = 8), dupilumab 
(N = 1), no biologicals (N = 1), and with healthcare professionals (N = 2) in the Netherlands. 
Our analysis focuses on patients’ experiences with the burden of disease and the burden 
of treatment regarding severe asthma.
Results:  Findings show how our respondents experience a high burden of disease 
(breathlessness, fatigue, exacerbations, loss of family, friends and employment) and treatment 
(oral corticosteroids’ side-effects, dependency, life-style changes). Treatment with biologicals 
is relatively new for respondents. They mention to be cautious in their embrace of biologicals 
and in expressing hope for the future. Respondents who react to treatment with biologicals 
experience relief of both the burden of disease and treatment. They aim to regain their 
social life and societal participation, a contrast to those for whom biologicals prove ineffective. 
Biologicals’ burden of treatment is experienced as low and minor side-effects are mentioned 
by three respondents. Respondents appear relatively unconcerned about the lack of 
knowledge concerning the long-term effects of biologicals.
Conclusions: Effective treatment with biologicals is generally experienced as a cautiously 
optimistic next step in a much longer and complex process of living with severe asthma. 
The practical lessons we draw point to managing patients’ expectations and the need to 
pay attention to patients not eligible for treatment with biologicals.
Introduction
Over the past 15 years, the diagnosis of ‘severe asthma’ 
has evolved. According to the current universally 
accepted definition, severe asthma is: ‘asthma which 
requires treatment with a high dose of inhaled cor-
ticosteroids (ICS) plus a second controller (and/or 
systemic corticosteroids) to prevent it from becoming 
‘uncontrolled’ or which remains ‘uncontrolled’ despite 
this therapy (1: p.344) (1). Only about 3–5% of the 
total asthma population suffers from severe asthma. 
This relatively small subgroup uses about 60% of the 
resources for treatment. This is mainly due to their 
high use of medication (2). Because of these differ-
ences, developing from medical and pathological dif-
ferences, calls have emerged to distinguish severe 
asthma more explicitly from milder asthma (3).
From the early 2000s specific medicines for asthma 
called ‘biologicals’ have emerged (1). Biologicals are 
monoclonal antibodies that influence the immune sys-
tem directly by blocking a specific messenger protein, 
interleukin, that is involved in inflammation processes 
(biologicals work on immunoglobulin E (IgE 
interleukin-4 receptor (IL4) (R), interleukin-5 (receptor) 
(IL5(R)) and interleukin-13 (IL13). Anti-IL-5 reduces 
eosinophilic inflammation in asthma by inhibition of 
eosinophil maturation and survival (2). Biologicals are 
add-on treatments such as omalizumab (Xolair®, 2003, 
IgE), mepolizumab (Nucala®, 2015), reslizumab 
(Cinquero®) (2016, IL-5), benralizumab (Fasenra®, 2017, 
IL-5R), and most recently dupilumab (Dupixent®, 2019, 
IL4R). Only about 50% of patients with severe asthma 
meet the criteria for treatment with these biologicals, 
as this depends on the type of inflammation and which 
© 2021 the author(s). Published with license by taylor & francis Group, llC.
CONTACT m. B. de Graaff  degraaff@eshpm.eur.nl   Erasmus school of health Policy & management, Erasmus university rotterdam, rotterdam, 
the netherlands.
https://doi.org/10.1080/02770903.2021.1888976
this is an open access article distributed under the terms of the Creative Commons attribution-nonCommercial-noDerivatives license (http://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not 
altered, transformed, or built upon in any way.
ARTICLE HISTORY
received 14 september 2020
revised 14 January 2021
accepted 8 february 2021
KEYWORDS
severe asthma; biologicals; 
burden of disease; burden of 
treatment; patient experience; 
benralizumab; qualitative 
research (Quality of life; Control/
management)
2 M. B. DE GRAAFF ET AL.
interleukins are involved. For patients with severe 
eosinophilic, T helper type 2 cells (Th2) driven, asthma 
the addition of biologicals to their treatment has proven 
to be effective in order to regain control over the dis-
ease, such as reducing asthma exacerbations (4). 
Clinical trials show biologicals having a ‘relatively favor-
able safety profile’ (5: p. 747, cf. 6,7). Novel approaches 
and therapies are needed for patients with severe 
non-eosinophilic asthma for whom currently available 
biologicals are not effective.
There is little research published that addresses 
patients’ experiences of living with severe asthma, and 
to the best of our knowledge, no interpretive research 
has been executed that explores the use of biologicals 
for this group of patients (8). Such an exploration is 
highly relevant in order to provide the necessary lived 
context to existing technical pharma-economical and 
epidemiological research on the use of biologicals for 
severe asthma. In this paper we focus on patients’ 
experiences with biologicals. However, we also pay 
attention to the experience of living with severe 
asthma in general at the same time as the experiences 
with this type of drugs will be connected to patients’ 
experiences with the disease in daily life life and past 
experiences with treatments.
The literature on the impact of living with chronic 
conditions, such as asthma, in daily life focuses on 
the burdens caused by these conditions. Firstly, this 
literature identifies a burden of disease; the burden 
of symptoms that patients experience. Secondly, it 
identifies a burden of treatment; the experience of 
patients ‘new and growing demands to organize and 
coordinate their own care, to comply with complex 
treatment and self-monitoring regimes, and to meet 
a whole range of expectations of personal motivation, 
expertise and self-care’ (9: p0.2). The burden of treat-
ment thus refers to the engagement of patients with 
their own (chronic) conditions that cannot be cured 
but rather must be managed.
From the few studies that have been done on expe-
riences of patients we can distill that suffering from 
severe asthma shows high burdens of disease and treat-
ment, although the experiences of patients are not 
conceptualized as such in these studies. Applying this 
conceptualization, we can conclude from these studies 
that burden of disease is high. Patients find themselves 
continually short of breath, fatigued, at risk of fearful 
exacerbations, unable to breathe, and in need of regular 
medication, while dealing with anxiety and depression 
(3,10). Besides physical distress, patients report living 
in fear, experience loss of contact with friends and 
family, and are unable to work. The latter also causes 
financial burdens (8,11). Burden of treatment for severe 
asthma is also high. It includes regular use of medi-
cation with (risks of) side-effects, especially oral cor-
ticosteroids (OCS), and large lifestyle changes such as 
weight management, exercise, smoking cessation, and 
avoiding triggers at work, home, and in everyday social 
life (8,12–14). The burden of treatment also involves 
health care utilization, such as repeated hospital visits 
and stays. Moreover, calls for patient empowerment 
and self-management can be found in literature on 
patients with severe asthma (15). As self-management 
shifts responsibilities to patients, it can further increase 
the burden of treatment.
This paper focuses on exploring the burden of dis-
ease and burden of treatment in patients with severe 
asthma and treated with biologicals. In doing so, we 
respond to the call for in-depth insight into the lived 
experience of severe asthma patients treated with bio-
logicals (8) by reporting on a qualitative study from 
the Netherlands.
Methods
Our qualitative exploratory research involved two 
steps: an analysis of patient experience stories and an 
interview-study with a life-history approach.
Firstly, we analyzed existing Dutch written patient 
narratives. Eighteen books were selected from the 
collection of 5409 patient narratives at the library of 
the Erasmus University Rotterdam1 using the theme 
‘asthma’. We excluded eleven books after a first read-
ing of the material, selecting the seven books written 
by patients living with severe asthma (16–22). We 
identified two further publications through our inter-
view study (23,24). None of the publications focused 
on the use of biologicals. However, they did provide 
us with the opportunity to gain in-depth insight into 
the experiences of living with the condition.
Secondly, building on the insights gained from the 
patient narratives, we interviewed patients (n = 10) and 
healthcare professionals (n = 2). The patient interviews 
were approached as “life-histories” in which we gave 
patients the opportunity to share their own experi-
ences, in their native language (Dutch), without 
over-structuring the interview (25,26). The researcher 
used open-ended topics to elicit spontaneous discus-
sion on patient experience in patient’s own words. 
Topics were, except for biologicals, derived from the 
patient narratives and included: experiences in every-
day life, finding a diagnosis, getting treatment. This 
approach enabled us in our aim to seek diversity in 
patients’ own narratives on daily life with severe 
asthma and the impact of biologicals. The patient 
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interviews were supplemented with two interviews 
with specialized health care personnel (respiratory 
nurse, pulmonologist). These interviews helped us to 
contextualize the patient interviews.
For the interviews we purposefully selected patients 
using a specific biological, benralizumab2 and included 
patients who are currently using benralizumab suc-
cessfully and those that have (recently) stopped. In 
order to develop a broader understanding of the 
themes related to the therapeutic area as a whole, we 
also included patients who use(d) other biologicals 
and one patient who had no experience with biolog-
icals and was diagnosed with allergic severe asthma. 
Details on respondents can be found in Table 1.
Respondents were selected from four nonacademic 
Dutch hospitals with tertiary severe asthma referral 
centers spread out across the Netherlands. AstraZeneca 
provided assistance for the selection of hospitals, how-
ever the researchers remained fully independent in 
their decision to adopt or reject the input. Physicians 
informed patients of the study and the primary 
researcher contacted them when they expressed the 
wish to participate. Interviews were, in all cases except 
for one (P008), executed in the homes of the respon-
dents and lasted between 43 min (P009) and 86 min 
(P003) with an average of 56 min. Respondents P004 
and P005 were interviewed together, and respondent 
P010 requested his wife to be present during the inter-
view. All respondents consented to have their inter-
view audio recorded, no incentives were offered for 
participation. Recordings were subsequently tran-
scribed verbatim to enable detailed analysis.
The written patient narratives and interviews were 
analyzed abductively through iterative thematic reading 
of the material; moving back and forth between the data 
and the literature (27,28). The initial coding scheme 
(available upon request) thematically categorized how 
respondents give meaning to the burden of severe 
asthma on their lives, the burden of care and the impact 
of biologicals. Atlas.ti software was used to aid the 
analysis. The analysis was jointly done by the first and 
third author.
This study was given positive ethical advice (MEC-U, 
W19.113/NWMO 19.05.023), following the guidelines 
from the Dutch Clinical Research Foundation (DCRF) 
for non-interventional studies, and was performed in 
accordance with ethical principles that are consistent 
with the Declaration of Helsinki, ICH GCPs, GPP and 
the applicable legislation on Non-Interventional Studies 
and/or Observational Studies.
Results
In this section, we first discuss the burden of disease 
and the burden of treatment of living with severe 
asthma before we comment on the lived experiences 
with using biologicals. Table 2 provides an overview 
of the main findings.
Burden of disease: dealing with symptoms
Our empirical results on patients’ experiences of the 
burden of disease align with the existing literature. 
An important part of this burden consists of having 
trouble breathing:
‘… like a fish on dry land, yes, that’s how I feel. Hoping 
for air, everything in my whole body tries to just catch 
this tiny little breath of air’ (19: p.206).3
Breathlessness and other symptoms like coughing 
can reach high severity and frequency. Patients refer 
to being identified by their symptoms:
‘Also, in my work, they said: ‘I do not know the name 
of that lady, but that is the lady who always coughs, 
So… yes, that’s what they said of me. I am known as 
‘that lady who coughs so much’ (Respondent P009).
Severe asthma can be complicated by severe exac-
erbations which are difficult for the respondents to 
control. They are described as intense and fearful 
Table 1. overview of respondents.
respondent Gender Year of birth Education (Dutch level) Biologicals (effect*)
P001 Woman 1965 secondary vocational education (mBo) benralizumab (responder)
P002 Woman 1972 secondary vocational education (mBo) omalizumab (non-responder), benralizumab (non-responder)
P003 Woman 1963 secondary vocational education (mBo) mepolizumab (non-responder), benralizumab (decreasing response)
P004 man 1954 higher professional education (hBo) dupilumab (responder)
P005 Woman 1956 higher professional education (hBo) none (non- eosinophilic severe asthma)
P006 Woman 1968 PhD (Doctor) benralizumab (responder)
P007 man 1970 higher professional education (hBo) omalizumab (non-responder), benralizumab (responder)
P008 Woman 1968 secondary vocational education (mBo) benralizumab (responder)
P009 Woman 1952 secondary vocational education (mBo) benralizumab (responder)
P010 man 1951 Primary education (Basisonderwijs) benralizumab (responder)
a001 Pulmonologist
a002 Pulmonary nurse-specialist
*Effect as mentioned by the respondent during the interview.
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experiences. Severe exacerbations and prolonged 
extreme breathlessness may require respondents to be 
hospitalized for weeks, sometimes leading to recurrent 
hospitalizations. Some respondents and authors have 
been hospitalized for more than 15 times. This is 
experienced as very frustrating, and the sheer fre-
quency appears to influence care-seeking:
‘I just want to be normal, just live … I refuse any 
admittance because I just don’t want to let my health 
ruin another year, I want to stop worrying about my 
health!’ (19: p.67).
To ‘just live’ is difficult for respondents. At the 
time of the interview, some respondents still had reg-
ular paid employment (P004, P006, P007), or have 
continued working until retirement, but most were 
not able to do so. The impact on other aspects of 
social life can also be large. With symptoms being 
unpredictable and energy-levels low, respondents 
shared many examples concerning the importance of 
controlling triggers in order to avoid exacerbations. 
Avoiding asthma triggers has strong consequences for 
respondents’ social life and societal participation. 
Many respondents share the same emotional experi-
ence, like losing friends and family because of having 
to deal with triggers affecting their symptoms, such 
as the use of perfume or smoking tobacco. Respondents 
mention that they struggle with people’s incompre-
hension of the severity of their asthma and, as a con-
sequence, do not disclose their illness easily. P007 is 
adamant in his determination with which he states 
not to be open about his disease, he does not want 
to appear sick and weak:
‘People are though, the only one being hurt is me, 
because people say: ‘[P007] is the klutz of the neigh-
borhood, we will ask someone else to help’ […] so I 
just didn’t say anything anymore, so I am involved 
and my life remained intact’ (P007).
Burden of treatment: the diagnosis and 
managing treatment
Whereas respondents seek ways to regain control and 
autonomy in their everyday lives, treatment for severe 
asthma is often insufficient. Respondents (except for 
P005 and P010) share an experience in exhibiting 
symptoms of asthma throughout their lives but have 
only recently been diagnosed with ‘severe eosinophilic 
asthma’. They tell stories that generally consist of 
patients and healthcare professionals ‘muddling 
through’ symptoms and exacerbations with prednisone, 
anti-biotics, etcetera – for most of our respondents, 
culminating in receiving benralizumab. Biologicals can 
play a part in this diagnostic process for patients:
‘I have always accepted that I had asthma, okay, and 
I am very happy that now, in fact, it has the stamp 
of this is it and nothing else. You can say that the 
syringe [benralizumab] is effective for me, but first, see 
if it really works for me […] after two injections I had 
something like, this oh yes this is it, finally’ (P001).
The realization of P001 is the final step in a long 
diagnostic process. Nonetheless, respondents appear 
to have a strong sense of trust in their current health-
care professionals. Regular checkups, controls and 
advice are deemed important – even though such tests 
are found to be strenuous themselves. Respondents 
who appear more able and willing to navigate their 
own healthcare also often appear critical of care pro-
fessionals. Especially issues in the communication 
between specialists and patients can be experienced 
as increasing the burden of treatment, for instance, 
when specialists such as P007’s ENT specialist and 
pulmonologist do not consult one another.
In the stories of patients, regular use of different 
kinds of medication is another prominent part of the 
burden of treatment. Respondents mention always 
needing to have a stock of medication readily available 
and share feelings regarding dependency. Some 
respondents have a rather ambivalent relationship to 
their medications and treatments, whereas others seem 
to be more straightforwardly at ease with it. Oral 
corticosteroids (OCS), prednisone, are mentioned 
more explicitly either as something that kept them 
going despite all odds or as medicine to be avoided 
– mainly because of the side effect of feeling bloated. 
Respondents also mention treatment with a strong 
focus on self-management techniques, for example, by 
practicing breathing and inhaler-techniques or creating 
an exacerbation plan with the nurse (A002). 
Respondents mention learning such self-management 
principles, linked to a more holistic perspective of a 
Table 2. overview of the main findings.
themes findings
Burden of disease Dealing with symptoms and their unpredictability, low-energy, large consequences for social life and societal participation, 
struggling with general incomprehension of society.
Burden of treatment long process of diagnosis, ‘muddling through’ care, high dependency on medication, focus on self-management.
Biologicals learning about this treatment option through specialist, low burden of treatment including limited worries on long-term 
effects and dependencies. Decreasing burden of disease by regaining lost social life and societal participation when 
effective. Burdens potentially increase when not effective.
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patients’ life, rather effectively in revalidation centers. 
This is also simultaneously experienced as a very 
intense step: removing oneself from existing routines 
in everyday life is an integral part of the treatment.
Respondents generally state to adhere to their pre-
scribed treatment, while at the same time giving ample 
examples of moments in which they have taken mat-
ters into their own hands. This can consist of using 
complementary medicine, but it is also expressed as 
learning to feel your own body and predicting flares, 
to such an extent that respondents argue against the 
doctor if necessary:
‘Yes, I had a fight with that new doctor who said: 
‘no, I am against prednisone’. Yes, I said you can be, 
but I have an agreement, [with her regular GP] I feel 
my own body. ‘Well yes, I will give you antibiotics’, 
the doctor said, and I said: ‘You can do it but on the 
weekend, I’ll call [my GP] immediately, so then I got 
[prednisone] anyway’ (P001).
This new doctor made the self-management effort 
of this respondent more difficult. This shows how 
patients can struggle to engage healthcare profession-
als in meaningful ways, and how such management 
is very much interaction between different actors. 
Interestingly, our interviews where the spouse of the 
patient was present as well (P004/P005 and P009) 
show how ‘self ’ management is a shared rather than 
individual effort; P005 seems to follow his wife in 
her efforts, and P001 reasons with her family, and 
her daughters, all the time.
Living with biologicals: cautiously embracing the 
last straw
Our respondents talk about the use of biologicals in 
the context of their experiences regarding the burden 
of disease and treatment. They have generally just 
recently learned of the existence of biologicals, mostly 
through their specialist. Respondents with relevant edu-
cation and experience (such as P006) do mention to 
have researched possible treatments on Google and 
Pubmed. Other patients also heard about this treatment 
option through the national patient organization for 
asthma (Longfonds) or the media, - such as reports 
on the ‘magic drug’ from Bennie Jolink [regional celeb-
rity folksinger]. Most respondents appear hopeful but 
reasonably sober in their expectations about biologicals. 
Their emotions, hopes and expectations are also actively 
managed by healthcare professionals.
Most respondents have recently started using bio-
logicals, sometimes in an experimental setting that 
requires quite some work from the respondents. 
However, respondents tend to be rather opaque about 
the actual use of biologicals; if it is about a shot, they 
must visit the hospital every now and then and exten-
sive training is not required. This indicates a lower 
burden of treatment:
‘‘The first time I got it I had to wait for two hours 
because you can get side effects and […] then you get 
the medicine a month later again, because it is every 
month, and then you just see your lung values going 
up. Once you see more lung capacity without having 
increased my medication, I think: ‘hey, that’s funny 
stuff. It works!’ (P007).
For some respondents, the monthly visits are also 
a comforting affair. It is nice to have tests and con-
trols, and the meetings with the specialist or nurse 
can be encouraging. The relatively new concept for 
patients to inject themselves at home is accompanied 
by some worries about less frequent controls at the 
hospital. Hence, this next step in treatment, intended 
to alleviate the burden of treatment, might for some 
patients in fact increase it.
The respondents for whom benralizumab is working 
well are positive about the effects - it allows them to 
reboot their social life and societal participation. The 
main positive effect they mention is to be able to sig-
nificantly reduce or stop the use of prednisone. 
According to respondents, that effect is usually achieved 
directly after the first injection. Interestingly, the com-
mon reaction is not elation when able to do something 
new, but instead, it is about regaining what has been 
lost. This experience is joyful to respondents, but also 
rather precarious; it is contextualized within their exist-
ing experiences of the burden of disease and treatment. 
Most respondents continue to need prednisone and 
inhalers and need to continue making lifestyle changes. 
In that sense, biologicals are really an ‘add-on’ treatment, 
an extra but important ‘last straw’ to be grasped with 
both hands (wife of P010). However, successful treat-
ment with biologicals is not the case for all respondents. 
Respondent P002, for instance, mentions her frustration 
that the biologicals do not really seem to affect her:
‘Inhalers and the other medication did not do much 
anymore, so then we searched for another possibility. 
[omalizumab] came into the picture, so for five years 
I had that, but I was admitted to the hospital quite a 
few times […] And that was also the only biological 
so far because I have had five or six, which I think 
helped me […] but good, in November I will start a 
new one’ (P002).
P002 has been taking biologicals since becoming 
available, generally to no avail. Still, she does pin her 
hopes on the next and new biological (dupilumab). 
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Perhaps because of this ‘last straw’ approach to the 
biologicals, only three respondents talk explicitly about 
side effects of biologicals such as heavy sweating (P008). 
Almost all respondents are aware of the lack of scientific 
understanding of the long-term effects of the use of 
biologicals. They do not seem to worry too much about 
them despite the potential life-long dependency, only 
the possibility that it negatively affects the immune 
system is mentioned. Instead, their focus is on the pres-
ent: respondents mention for instance that they are 
simply happy to be able to go on a holiday (P003).
Discussion
Little is written about the way patients with severe 
asthma experience the burden of disease and treatment, 
and even less is known about how these patients con-
sider treatment with biologicals (8). Our findings show 
that patients with severe asthma experience a high 
burden of disease. This burden moves beyond the 
boundaries of the experience regarding the symptoms 
(shortness of breath, coughing, fatigue, etc.) to diffi-
culties with (intimate) social interaction and societal 
participation (13–15), and includes living with incom-
prehension and in fear (8,29). The burden of treatment 
appears similarly high and to consist of the regular use 
of, and dependency on, medication with risks of 
side-effects combined with large lifestyle changes. 
Dependency on, and side effects of, OCS dominate 
how respondents discuss their treatment (6,12,13). 
Treatment burden also includes many interactions with 
healthcare professionals and repeated (emergency) visits 
to hospitals and revalidation centers. Generally, our 
respondents show high trust in the professionals cur-
rently treating them and we have found relatively few 
moments of tension between lay and expert knowledge 
that might compound frustration and uncertainties – 
although comprehensive information is not accessible 
to all severe asthma patients (30–32). A good relation-
ship with professionals, partners and friends can alle-
viate burden of treatment. In cases where such 
relationships are harder to find respondents feel they 
have to take matters in their own hands. This poten-
tially heightens the burden of disease.
Severe asthma patients’ self-management is gener-
ally dominated by ideas of adherence and control 
derived from evidence-based clinical guidelines (33–
35). However, based on our results, we support the 
call to reconsider the nature of self-management, the 
asthma action plans that are meant to support it and 
to thoroughly value the patient’s daily life experience. 
Intentions and initiatives from doctors and health care 
institutions, concerning shared decision-making, 
self-management, home treatment and monitoring by 
E-Health, may thus not always be in line with the 
patient’s needs or wishes. This is especially important 
because the main impetus for patient self-management 
is to enhance autonomy in everyday life and gain 
control over their disease (15).
Biologicals are meant to serve as add-on medication 
and if they are effective, appear to significantly lighten 
the burden of treatment (8,13). We indeed find that, 
when effective, the positive impact on both the burden 
of disease and treatment can be high. However, most 
of our respondents appear cautious in their embrace 
of biologicals and in expressing hope for the future. 
This may be related to their turbulent patient journeys. 
Respondents’ tentative position to biologicals appears 
to be justified considering that for some respondents, 
biologicals do not seem to be effective or the effects 
diminish over time. These patients resume an everyday 
life dominated by severe asthma. To return to such a 
situation might even increase the experienced burden 
of disease and treatment. This group of patients con-
tinues to be rather invisible to the broader public and 
to be at risk of social isolation. The efficacy of biolog-
icals potentially further obscures this group as clinical 
attention is drawn to the success of these new treat-
ment options. It seems important to ensure that a con-
crete focus on improving the burden of disease and 
treatment in the everyday lives of all patients, including 
patients with non-Th2 inflammation, suffering from 
severe asthma is maintained.
Limitations and future research
In this research we conducted an exploratory quali-
tative study with a small sample size. Such a design 
proves effective for exploring commonalities in 
patient’s experience and narratives, but is limited in 
for instance, comparisons between different sub-groups 
of patients suffering from severe asthma. Future 
research should consider to detail differences between 
experiences of patients of different educational back-
grounds or between responders and non-responders 
to biologicals as we could only provide indications of 
variation. Also, most of our respondents are using 
benralizumab and exhibit a positive response to treat-
ment, our results may be biased on these issues and 
future research could consider more variation in terms 
of biologicals used and in terms of responders and 
non-responders. Other interesting comparisons would 
be to compare the perceptions of (the burden of) 
treatment between patients and healthcare 
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professionals. This might bring to light more concrete 
information on how to further improve self-management 
and communication. Comparing the experiences of 
patients across healthcare systems would also be inter-
esting. For example, our respondents did not mention 
the relative high costs of biologicals (5), which could 
be an effect of the Dutch healthcare system in which 
biologicals are insured without out-of-pocket costs for 
eligible patients. Another limitation of this study is 
that, although we have strived to discuss patients’ 
experiences over time through our life-history inter-
views, we only collected data on one point in time. 
For future research it is important to gauge if and 
how patients’ experiences of biologicals develop over 
time using a repeated longitudinal design.
Conclusions
Severe asthma poses a significant burden of disease 
and treatment on patients, families and healthcare 
systems. By performing this study, important lessons 
have been learned based on everyday experiences of 
patients living with severe asthma and receiving treat-
ment with biologicals. These lessons can have impli-
cations for daily healthcare practice, see Table 3.
Lessons reported in this study include the impor-
tance of timely and accurate diagnosis of (severe) 
asthma, the availability of supportive communication 
with health care providers, the relevance of patients’ 
perspective on everyday life with self-management 
strategies, and attention to the invisibility of severe 
asthma patients not eligible for treatment with biolog-
icals. Most importantly, severe asthma generally still 
seems to be a rather ‘invisible disease’, and more atten-
tion could be paid to the burden of disease and treat-
ment experienced by patients. It is important for 
clinicians, scientists, politicians and healthcare insur-
ance companies to join forces to help all severe asthma 
patients deal with this ‘hidden burden’ of severe asthma.
Notes
 1. See: https://www.eur.nl/library/collecties/
collectie-patientervaringen
 2. Benralizumab is administered using a syringe, once 
every 8 weeks, with a loading dose in week 
4, about 8-6x times a year – a much smaller 
frequency than the daily medication patients 
with severe asthma are accustomed to. Tests by, 
amongst others, the pharmaceutical company 
show it to be a rather successful add-on treat-
ment; 74% of patients report no exacerbations of 
severe asthma in their second year of taking it. 
Overall, biologicals’ greatest clinical benefit lies in 
reducing severe asthma exacerbations, with mod-
est effects on day-to-day symptoms and quality 
of life (1), thus diminishing the need for the use 
of oral corticosteroids, and prednisone, of which 
side-effects are relatively strong both physically 
(osteoporosis, cataract, blood pressure drops) and 
mentally (anxiety, irritability, depression).
 3. All quotes are translated from Dutch by the first 
author and edited for readability.
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